Kerri Bertrand1, Gordon Honerkamp-Smith1, Christina D Chambers1,2. 1. Division of Dysmorphology and Teratology, Department of Pediatrics, University of California, San Diego, La Jolla, California, USA. 2. Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, California, USA.
Abstract
Background: In December 2020, two novel messenger RNA (mRNA) vaccines for severe acute respiratory syndrome coronavirus-2 received emergency use authorization from the U.S. Food and Drug Administration; however, the early trials excluded lactating women. Methods: Breastfeeding women residing in the United States who received either of the two mRNA vaccines were enrolled into the Mommy's Milk Human Milk Research Biorepository at the University of California, San Diego. From December 14, 2020 to February 1, 2021, 180 women who received two doses of either mRNA vaccine were recruited into the study. Results: Similar proportions of women reported any one or more symptoms following vaccination with either mRNA vaccine. In addition, the frequency by specific type of symptom did not differ by brand. However, following the second dose of vaccine, women who received the Moderna brand were significantly more likely to report symptoms. A small proportion of women following the first dose of either vaccine brand reported a reduction in milk supply, and significantly, more women reported a reduction in milk supply following the second dose of Moderna. Few infant events were reported for either vaccine brand following either dose, and no serious adverse events were reported. Conclusions: These data are reassuring regarding the safety of vaccination in breastfeeding women and their breastfed children with either of the mRNA COVID-19 vaccines.
Background: In December 2020, two novel messenger RNA (mRNA) vaccines for severe acute respiratory syndrome coronavirus-2 received emergency use authorization from the U.S. Food and Drug Administration; however, the early trials excluded lactating women. Methods: Breastfeeding women residing in the United States who received either of the two mRNA vaccines were enrolled into the Mommy's Milk Human Milk Research Biorepository at the University of California, San Diego. From December 14, 2020 to February 1, 2021, 180 women who received two doses of either mRNA vaccine were recruited into the study. Results: Similar proportions of women reported any one or more symptoms following vaccination with either mRNA vaccine. In addition, the frequency by specific type of symptom did not differ by brand. However, following the second dose of vaccine, women who received the Moderna brand were significantly more likely to report symptoms. A small proportion of women following the first dose of either vaccine brand reported a reduction in milk supply, and significantly, more women reported a reduction in milk supply following the second dose of Moderna. Few infant events were reported for either vaccine brand following either dose, and no serious adverse events were reported. Conclusions: These data are reassuring regarding the safety of vaccination in breastfeeding women and their breastfed children with either of the mRNA COVID-19 vaccines.
Entities:
Keywords:
COVID-19; SARS-CoV-2; breastfeeding; human milk; lactation; mRNA vaccine; vaccination
Authors: Kathryn J Gray; Evan A Bordt; Caroline Atyeo; Elizabeth Deriso; Babatunde Akinwunmi; Nicola Young; Aranxta Medina Baez; Lydia L Shook; Dana Cvrk; Kaitlyn James; Rose De Guzman; Sara Brigida; Khady Diouf; Ilona Goldfarb; Lisa M Bebell; Lael M Yonker; Alessio Fasano; S Alireza Rabi; Michal A Elovitz; Galit Alter; Andrea G Edlow Journal: Am J Obstet Gynecol Date: 2021-03-26 Impact factor: 8.661
Authors: Ae Ra Han; Dayong Lee; Seul Ki Kim; Chang Woo Choo; Joon Cheol Park; Jung Ryeol Lee; Won Jun Choi; Jin Hyun Jun; Jeong Ho Rhee; Seok Hyun Kim Journal: Clin Exp Reprod Med Date: 2022-02-28
Authors: L Ryan; Frans B Plötz; Agnes van den Hoogen; Jos M Latour; Marina Degtyareva; Maya Keuning; Claus Klingenberg; Irwin K M Reiss; Eric Giannoni; Charles Roehr; Christopher Gale; Eleanor J Molloy Journal: Pediatr Res Date: 2021-12-28 Impact factor: 3.953
Authors: Joke Muyldermans; Louise De Weerdt; Larissa De Brabandere; Kirsten Maertens; Eline Tommelein Journal: Front Immunol Date: 2022-04-08 Impact factor: 8.786